Absci's Integrated Drug Creation platform pairs generative-AI antibody design with its SoluPro microbial cell-line protein production system.
Absci's Integrated Drug Creation platform uses generative artificial intelligence to design therapeutic antibodies in silico and validates candidate molecules through its proprietary SoluPro cell-line system. SoluPro expresses fully human antibodies in microbial cells, linking computational design to protein production within a single workflow.
The platform supports target-specific antibody generation and high-throughput screening for Absci's internal pipeline and partnered programs. Combining AI-driven antibody design with microbial protein production positions Absci to compress the timeline from discovery to developable therapeutic candidates.
| Attribute | Absci Integrated Drug Creation Platform | EXIS | |
|---|---|---|---|
| Provider |  |  | |
| Founded | 2011 | 2016 | |
| Sells To | Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring, Software | |
| Ownership | Public | Private equity-backed, Venture-backed |
Provider
Founded 2011
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider
Founded 2016
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private equity-backed, Venture-backed
Generate Platform is a generative biology platform that designs novel protein therapeutics.
AbCellera offers its antibody discovery and development platform to biopharma partners for co-discovery and co-development of antibody medicines.
OmniAb is an antibody-discovery platform built on transgenic OmniRat, OmniMouse, and OmniChicken hosts that produce fully human antibodies.
Adimab's antibody discovery platform uses an engineered yeast system and fully human libraries to isolate therapeutic antibodies.
Generate Platform is a generative biology platform that designs novel protein therapeutics.
AbCellera offers its antibody discovery and development platform to biopharma partners for co-discovery and co-development of antibody medicines.
OmniAb is an antibody-discovery platform built on transgenic OmniRat, OmniMouse, and OmniChicken hosts that produce fully human antibodies.
Adimab's antibody discovery platform uses an engineered yeast system and fully human libraries to isolate therapeutic antibodies.